Bariatric surgery associated with lower cardiovascular risks than GLP-1RA therapy in adults with obesity
Study finds bariatric surgery linked to lower heart risks than GLP-1 drugs in adults with obesity
A meta-analysis of observational studies including 39,569 adults with obesity found bariatric surgery was associated with lower risks of mor…
Adults with obesity who had bariatric surgery faced lower risks of death and heart failure than those taking GLP-1 drugs like Wegovy.
GLP-1RA use associated with lower obesity-related cancer risk in meta-analysis of adults with T2DM/obesity
Large review finds link between GLP-1 drugs and lower obesity-related cancer risk
A systematic review and meta-analysis of 3,960,974 adults with type 2 diabetes and/or obesity found GLP-1RA use was associated with a signif…
A large review of studies involving nearly 4 million adults with type 2 diabetes or obesity found that using GLP-1 receptor agonists was ass…
Retrospective study of semaglutide in 17 patients with type 2 diabetes and end-stage renal disease
Can a diabetes drug help people with kidney failure? A small study looks for clues
A retrospective cohort study of 17 adults with T2DM and ESRD (including those on hemodialysis) found descriptive reductions in HbA1c (-0.31%…
A small study found that injectable semaglutide helped adults with kidney failure lose an average of 12.6 kilograms while reducing insulin n…
FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults
FDA approves a new treatment for a serious lung condition called pulmonary arterial hypertension
The FDA has approved Winrevair for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capac…
A new FDA-approved injection helps adults with pulmonary arterial hypertension exercise longer, improve daily life, and lower the risk of ho…